Leptospirosis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Leptospirosis Market is Segmented by Treatment Type (Penicillin, Ampicillin, Doxycycline, Ceftriaxone, Azithromycin, Tetracycline, and Others), Diagnosis (Microscopic Agglutination Test, Complete Blood Count, Urinalysis, and Others), and End Users (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Leptospirosis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Leptospirosis Market Size

Leptospirosis Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 6.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Leptospirosis Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Leptospirosis Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Leptospirosis Market Analysis

The Leptospirosis Market is expected to register a CAGR of 6.1% during the forecast period.

The COVID-19 pandemic severely impacted the leptospirosis market initially, with the temporary cancellation or delays in diagnosing and treating various non-COVID diseases, including leptospirosis infection. However, several countries reported growth in leptospirosis cases amid the outbreak. For instance, a study published in the Journal of Medical Virology in September 2022 stated that leptospirosis and coronavirus infection was endemic in the coastal regions of South India during the pandemic. Although, in the post-pandemic period, the cases of COVID-19 decreased, which led to the resumption of the leptospirosis treatment, which enabled the market to grow at the normal growth pace.

The leptospirosis market is expected to grow during the forecast period owing to the increase in the prevalence of leptospirosis and a surge in research and development activities for bacterial infections. For instance, a study published in Journal Pathogen in March 2022 stated that human leptospirosis infection is a leading and neglected source of morbidity and mortality, with more than 1 million cases and approximately 60,000 deaths per year. Further, a study published in the Journal Scientific Reports in January 2022 stated that a sampling of United States Virgin Islands (USVI) rodents determined that 45.7% (64/140) were carriers of pathogenic Leptospira species. The study stated that rodent exposure is associated with an increased risk of leptospirosis. The study also revealed that acute infections are more common in low-resource, tropical, and subtropical locations where outbreaks occur after natural disasters such as hurricanes, heavy rainfall, and flooding. With such a vast target population for leptospirosis infections, the market is likely to grow with higher demand for leptospirosis infection treatment in the coming years.

Furthermore, the activities in the research and developments for bacterial infections have increased, which is expected to boost the R&D of more leptospirosis treatment drugs and boost the market growth. For instance, in December 2021, a Research Project Grant from the Health Research Council of New Zealand (HRC) was awarded funding of NZD 1 million (USD 0.61 million) to Professor Jackie Benschop from the School of Veterinary Science. The research grant was awarded for the project "Enhancing leptospirosis diagnosis and outcomes for rural and Māori communities."

Therefore, the studied market is anticipated to grow over the analysis period due to the factors above, including the increasing prevalence of leptospirosis and the surge in research and development activities for bacterial infections. However, the lack of awareness about leptospirosis infections will likely impede market growth.

Leptospirosis Industry Overview

The leptospirosis market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The key players operating in the market include GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Cipla Inc, and Pfizer Inc.

Leptospirosis Market Leaders

  1. GlaxoSmithKline Plc

  2. Novartis AG

  3. AbbVie Inc

  4. Cipla Inc

  5. Pfizer Inc

  6. *Disclaimer: Major Players sorted in no particular order
Leptospirosis Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Leptospirosis Market News

  • In July 2022, Mylab Discovery Solutions launched 'PathoDetect Extended Monsoon Fever Panel,' which is a comprehensive multiplex RT PCR test kit for all monsoon diseases such as malaria, chikungunya, dengue, Zika, leptospirosis, and salmonellosis bacterial species, and Leishmaniasis parasites.
  • In April 2022, the health ministry of Kerela state of India launched a campaign, 'Mrityunjayam,' to promote awareness about leptospirosis, as the monsoon season increases the risk of leptospirosis.

Leptospirosis Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Prevalence of Leptospirosis
    • 4.2.2 Surge in Research and Development Activities for Bacterial Infections
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness about Leptospirosis Infections
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Treatment Type
    • 5.1.1 Penicillin
    • 5.1.2 Ampicillin
    • 5.1.3 Doxycycline
    • 5.1.4 Ceftriaxone
    • 5.1.5 Azithromycin
    • 5.1.6 Others
  • 5.2 By Diagnosis
    • 5.2.1 Microscopic Agglutination Test
    • 5.2.2 Complete Blood Count
    • 5.2.3 Urinalysis
    • 5.2.4 Others (Blood Culture and Liver Enzymes, among others)
  • 5.3 By End Users
    • 5.3.1 Hospitals
    • 5.3.2 Speciality Clinics
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.2 Europe
    • 5.4.3 Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.5 South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline plc
    • 6.1.2 Novartis AG
    • 6.1.3 AbbVie Inc.
    • 6.1.4 Cipla Inc.
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Lupin Limited
    • 6.1.7 Abbott Laboratories
    • 6.1.8 Zydus Group
    • 6.1.9 Aurobindo Pharma
    • 6.1.10 Baxter International Inc.
    • 6.1.11 Sun Pharmaceutical Industries Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Leptospirosis Industry Segmentation

As per the scope of the report, leptospirosis is a zoonotic illness that can spread from animals to humans, and it can infect both people and animals. Leptospirosis can be acquired through the nose, mouth, eyes, or skin abrasions when a person encounters water that the infected animals have polluted. The Leptospirosis Market is Segmented by Treatment Type (Penicillin, Ampicillin, Doxycycline, Ceftriaxone, Azithromycin, Tetracycline, and Others), Diagnosis (Microscopic Agglutination Test, Complete Blood Count, Urinalysis, and Others), and End Users (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for five different major regions globally.

By Treatment Type Penicillin
Ampicillin
Doxycycline
Ceftriaxone
Azithromycin
Others
By Diagnosis Microscopic Agglutination Test
Complete Blood Count
Urinalysis
Others (Blood Culture and Liver Enzymes, among others)
By End Users Hospitals
Speciality Clinics
Other End Users
Geography North America
Europe
Asia-Pacific
Middle East and Africa
South America
Need A Different Region or Segment?
Customize Now

Leptospirosis Market Research FAQs

What is the current Global Leptospirosis Market size?

The Global Leptospirosis Market is projected to register a CAGR of 6.1% during the forecast period (2025-2030)

Who are the key players in Global Leptospirosis Market?

GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Cipla Inc and Pfizer Inc are the major companies operating in the Global Leptospirosis Market.

Which is the fastest growing region in Global Leptospirosis Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Leptospirosis Market?

In 2025, the North America accounts for the largest market share in Global Leptospirosis Market.

What years does this Global Leptospirosis Market cover?

The report covers the Global Leptospirosis Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Leptospirosis Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Leptospirosis Industry Report

Statistics for the 2025 Leptospirosis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Leptospirosis analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.